Please login to the form below

secukinumab

This page shows the latest secukinumab news and features for those working in and with pharma, biotech and healthcare.

Novartis stumbles in Q2 as COVID-19 impacts sales

Its psoriasis and arthritis drug Cosentyx (secukinumab) also saw a sales rise of 12% to $944m, while its heart failure drug Entresto (sacubitril/valsartan) climbed 40% to $508m.

Latest news

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

The growth came despite another strong quarter for Novartis’ IL-17 inhibitor Cosentyx (secukinumab) in psoriasis – currently leading the charge among a new generation of biologic therapies for the skin disorder
Cosentyx, Entresto drive topline growth for Novartis in Q4

The 8% net sales increase was mainly driven by continued growth of Novartis’ newer drugs, namely its heart failure drug Entresto (sacubitril/valsartan), psoriasis treatment Cosentyx (secukinumab) and spinal muscular atrophy
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and
J&J splashes $750m on anti-inflammatory drug bermekimab

secukinumab) and AbbVie’s Skyrizi (risankizumab).
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

It is also investigating bimekizumab in a head-to-head trial with Novartis’ IL-17A inhibitor Consentyx (secukinumab) in psoriasis.

More from news
Approximately 15 fully matching, plus 84 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

multiple sclerosis and secukinumab for several inflammatory conditions. .

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...